Lung cancer combo shows promise after targeted therapy fails

NCT ID NCT05786430

Ongoing Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of lazertinib (a targeted pill) plus two chemotherapy drugs (pemetrexed and carboplatin) in 87 adults with a specific type of advanced lung cancer (EGFR mutation-positive non-small cell lung cancer) that has stopped responding to lazertinib alone. The main goal is to see how long the cancer stays under control. This is an active but not recruiting study in South Korea.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lazertinib plus pemetrexed and carboplatin
What this could lead to: If successful, this combination could offer a new treatment option for patients whose lung cancer has stopped responding to lazertinib alone.
What could go wrong: This is a mid-stage trial with only 87 participants, so results may not apply to everyone. Chemotherapy side effects are expected, and the cancer may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Yonsei University Health System, Severance Hospital

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.